Abbott Laboratories (ABT) Stock Price
Abbott Laboratories Price
Over the last 19 years Abbott Laboratories grew revenue by 3.6% annually, reaching 44.33 B USD. Earnings per share have grown at 6.6% per year over the last 19 years. For Abbott Laboratories, the net margin of 14.7% is down versus 16.4% a few years ago. At today's price the dividend yield works out to roughly 2.33%. The payout ratio is around 63% of earnings. The dividend has grown at 3.8% per year over the past 19 years. The consensus 12-month price target for Abbott Laboratories is 121.00 USD, about 19.5% above where the stock trades today. Of 33 analysts, 25 rate the stock a buy — an overall Buy consensus. The stock trades about 23% above its 52-week low.
Abbott Laboratories stock price
Abbott Laboratories business model & stock analysis
Frequently asked questions about Abbott Laboratories
Abbott Laboratories is a renowned healthcare company with a strong business model focused on providing a diverse range of medical products, diagnostics, nutritional supplements, and pharmaceuticals. By combining technological advancements with innovative research, Abbott aims to enhance the quality of life for individuals worldwide. With a comprehensive portfolio spanning diverse healthcare sectors, including diagnostics, nutrition, diabetes care, medical devices, and branded generic pharmaceuticals, Abbott Laboratories strives to improve patient outcomes and deliver sustainable growth. Through its commitment to scientific excellence and dedication to meeting evolving healthcare needs, Abbott Laboratories has established itself as a trusted leader in the global healthcare industry.
Abbott Laboratories is primarily active in the healthcare industry.
The main competitors of Abbott Laboratories in the market are Johnson & Johnson, Pfizer, and Roche Holding AG.
Abbott Laboratories is a renowned American healthcare company, known for providing a diverse range of medical, pharmaceutical, and nutritional products. Founded in 1888 by Dr. Wallace C. Abbott, the company initially focused on producing pharmaceuticals, including the widely successful alkaloid-based pain reliever, Abbott's ABC Liniment. Over the years, Abbott Laboratories has expanded its portfolio, venturing into areas such as diagnostics, medical devices, and nutrition. The company's commitment to innovation is evident through breakthroughs like the development of the first HIV blood-screening test. Today, Abbott Laboratories continues to play a crucial role in improving health outcomes worldwide, with its cutting-edge technology and a focus on delivering quality healthcare solutions.
Abbott Laboratories has achieved several significant milestones throughout its history. One major milestone was the development and commercialization of the first-ever HIV blood screening test, which greatly contributed to safer transfusions and the prevention of the spread of HIV. Additionally, Abbott Laboratories introduced breakthrough medical devices, such as the FreeStyle® Libre system, a continuous glucose monitoring system for diabetes management. The company also played a crucial role in the fight against COVID-19 by developing rapid diagnostic tests for the virus. Furthermore, Abbott Laboratories has consistently been recognized for its commitment to innovation and sustainability, making it a leading healthcare company globally.
Abbott Laboratories is primarily present in multiple countries and regions worldwide. The company operates in more than 160 countries, including the United States, Canada, Europe, Asia-Pacific, Latin America, and the Middle East. With a strong global footprint, Abbott Laboratories has established itself as a leading healthcare company in various markets, delivering innovative medical products, diagnostics, nutritionals, and pharmaceuticals to improve people's health and well-being.
Abbott Laboratories is committed to its core values of putting patients first, serving customers with innovative solutions, and operating with integrity in all aspects of its business. The company's corporate philosophy centers around improving life through the development of groundbreaking technologies and products. Abbott Laboratories prides itself on its dedication to delivering reliable healthcare solutions, fostering collaboration with healthcare professionals, and investing in research and development to address unmet medical needs. With a focus on providing high-quality and accessible healthcare options, Abbott Laboratories strives to create positive impacts in communities worldwide through its diverse portfolio of medical devices, diagnostics, nutrition, and pharmaceutical products.
Analysts currently set an average price target of 123.64 USD for the Abbott Laboratories stock (median: 121.00 USD), implying +22.1 % versus the latest price. The consensus is based on 33 analyst ratings.
33 analysts currently rate the Abbott Laboratories stock: 25 recommend buying, 8 holding and 0 selling. For 2026, analysts expect Abbott Laboratories to generate revenue of 50.31 B USD and earnings per share of 5.52 USD.
Converted at the current exchange rate, the Abbott Laboratories share trades at 88.88 EUR (101.29 USD).
The Abbott Laboratories share (ABT) is listed on 9 stock exchanges, including: NYSE (ABT), London (0Q15.L), SIX (Zürich) (ABT.SW), XETRA (ABL.DE), Frankfurt (ABL.F), München (ABL.MU), Düsseldorf (ABL.DU), Hamburg (ABL.HM).
Abbott Laboratories is a global company specializing in the development, manufacturing, and marketing of health products and services. Its business model is divided into different divisions that focus on the needs of patients, doctors, and healthcare systems. The divisions of Abbott Laboratories include Diagnostics, Medical Devices, Nutrition, and Pharmaceutical. The company aims to continuously develop innovative technologies and products to improve healthcare, and it offers a wide range of services and support programs for patients. Abbott Laboratories has established a strong market position and global presence in over 160 countries since its establishment in 1888. It also pursues a successful acquisition strategy to expand its product portfolio, such as the acquisition of St. Jude Medical in 2017 to enhance its cardiovascular products and services. Overall, Abbott Laboratories aims to improve healthcare and meet the needs of patients, doctors, and healthcare systems through its comprehensive strategy focused on developing innovative products, expanding into new markets, and increasing efficiency.
The expected revenue of Abbott Laboratories is 50.31 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Abbott Laboratories is 9.64 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Abbott Laboratories is currently 18.35. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Abbott Laboratories stock.
The price-to-sales ratio (P/S) of Abbott Laboratories is currently 3.52. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Abbott Laboratories stock.
The Eulerpool Quality Score for Abbott Laboratories is 6/10.
The ISIN of Abbott Laboratories is US0028241000. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Abbott Laboratories is 850103. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Abbott Laboratories is ABT. The ticker symbol is used to trade Abbott Laboratories shares on the stock exchange.
Over the past 12 months, Abbott Laboratories paid a dividend of 2.36 USD . This corresponds to a dividend yield of about 2.33 %. For the coming 12 months, Abbott Laboratories is expected to pay a dividend of 2.76 USD.
The current dividend yield of Abbott Laboratories is 2.33 %.
Abbott Laboratories pays a dividend, distributed in the months of October, January, April, July.
Abbott Laboratories paid dividends every year for the past 52 years.
For the upcoming 12 months, dividends amounting to 2.76 USD are expected. This corresponds to a dividend yield of 2.72 %.
Abbott Laboratories is assigned to the 'Health' sector.
In the year 2025, Abbott Laboratories distributed 2.36 USD as dividends.
The dividends of Abbott Laboratories are distributed in USD.
Abbott Laboratories stock
Abbott Laboratories Peer Group
Abbott Laboratories Ticker
Abbott Laboratories FIGI
All fundamentals and in-depth analysis of Abbott Laboratories
Our stock analysis for Abbott Laboratories stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Abbott Laboratories. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.